Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 9/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 9/20 | 0.59 |
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | CA9 | Q16790 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | F11 | P03951 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35211851 | 1.00 | PDE3B (0.59) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL29902532 | 0.74 | PDE3B (1.00) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL3385284 | 0.74 | PDE3B (0.71) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL30154352 | 0.74 | PDE3B (0.71) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL5366546 | 0.71 | PDE3B (0.52) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL29163284 | 0.71 | PDE3B (0.52) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL14494403 | 0.70 | CA12 (0.55) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL5365199 | 0.70 | PDE3B (0.50) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL14494413 | 0.70 | PDE3B (0.50) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL15507389 | 0.70 | PDE3B (0.50) | PDE3BPDE3ACA12CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420649-B2 | Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof | AMGEN INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110281864-A1 | Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-4996204-A | Antidiabetic agents | PFIZER INC. (US) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281864-A1 | Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof | MAPK1, MAPK3, MAP4K2 | PDE3B 562/4885PDE3A 558/4885CA12 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.